Travere Therapeutics Inc’s recently made public that its SENIOR VICE PRESIDENT, R&D ROTE WILLIAM E. unloaded Company’s shares for reported $47424.0 on Jan 22 ’25. In the deal valued at $19.46 per share,2,437 shares were sold. As a result of this transaction, ROTE WILLIAM E. now holds 83,170 shares worth roughly $1.69 million.
Then, Dube Eric M sold 10,736 shares, generating $208,923 in total proceeds. Upon selling the shares at $19.46, the CHIEF EXECUTIVE OFFICER now owns 351,239 shares.
Before that, REED ELIZABETH E sold 2,437 shares. Travere Therapeutics Inc shares valued at $47,424 were divested by the SVP, GC & CORPORATE SECRETARY at a price of $19.46 per share. As a result of the transaction, REED ELIZABETH E now holds 76,933 shares, worth roughly $1.56 million.
Cantor Fitzgerald initiated its Travere Therapeutics Inc [TVTX] rating to an Overweight in a research note published recently. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who increased its forecast for the stock in late October from “an Equal weight” to “an Overweight”. Scotiabank began covering TVTX with “Sector outperform” recommendation on October 16, 2024. Guggenheim revised its rating on September 09, 2024. It rated TVTX as “a Buy” which previously was an “a Neutral”.
Price Performance Review of TVTX
On Friday, Travere Therapeutics Inc [NASDAQ:TVTX] saw its stock fall -2.40% to $20.31. Over the last five days, the stock has gained 9.96%. Travere Therapeutics Inc shares have risen nearly 16.59% since the year began. Nevertheless, the stocks have risen 118.62% over the past one year. While a 52-week high of $20.89 was reached on 01/24/25, a 52-week low of $5.12 was recorded on 01/14/25. SMA at 50 days reached $18.37, while 200 days put it at $12.32.
Levels Of Support And Resistance For TVTX Stock
The 24-hour chart illustrates a support level at 19.86, which if violated will result in even more drops to 19.41. On the upside, there is a resistance level at 21.16. A further resistance level may holdings at 22.01. The Relative Strength Index (RSI) on the 14-day chart is 62.15, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.31, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 26.26%. Stochastics %K at 87.22% indicates the stock is a selling.
How much short interest is there in Travere Therapeutics Inc?
A steep rise in short interest was recorded in Travere Therapeutics Inc stocks on 2024-12-31, growing by 1.14 million shares to a total of 8.72 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 7.57 million shares. There was a rise of 13.13%, which implies that there is a positive sentiment for the stock.
